Immunovant, Inc. 10-Q Summary
Business context and reporting period
Immunovant is a clinical-stage biopharmaceutical company developing IMVT-1401, a fully human monoclonal antibody targeting the neonatal Fc receptor for IgG-mediated autoimmune diseases. The unaudited report covers the three and nine months ended December 31, 2019, with a March 31 fiscal year-end.
On December 18, 2019, Health Sciences Acquisitions Corporation completed its reverse recapitalization with Immunovant Sciences Ltd. and changed its name to Immunovant, Inc. The company began trading under IMVT, IMVTU and IMVTW on December 19, 2019. Historical financial statements primarily represent Immunovant Sciences Ltd. as the accounting predecessor.
Key financial metrics
| Metric | Three months ended Dec. 31, 2019 | Nine months ended Dec. 31, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $5.0 million | $33.8 million |
| General and administrative expense | $6.1 million | $11.8 million |
| Total operating expenses | $11.0 million | $45.6 million |
| Interest expense | $0.4 million | $0.6 million |
| Net loss | $11.3 million | $45.8 million |
| Net loss per share | $0.28 | $1.16 |
| Cash used in operating activities | Not separately provided | $30.3 million |
As of December 31, 2019, cash was $123.5 million, compared with $7.0 million at March 31, 2019. Total liabilities were $14.8 million, including $3.1 million due to Roivant Sciences Ltd.; the convertible promissory notes had converted into common stock before the Business Combination closed. Accumulated deficit was $70.7 million and stockholders’ equity was $111.9 million.
Profit margins are not meaningful because the company has no revenue. The company reported negative operating margins and continuing negative cash flow.
Material changes versus the prior comparable period
- Third-quarter net loss increased to $11.3 million from $8.8 million, primarily because general and administrative expense rose by $4.9 million, partly offset by a $2.7 million decline in research and development expense.
- Nine-month net loss increased to $45.8 million from $19.6 million. Research and development expense increased by $16.0 million, including a $10.0 million HanAll development and regulatory milestone payment, higher CRO costs and increased personnel costs.
- Nine-month general and administrative expense increased by $10.1 million to $11.8 million, driven by higher legal and professional fees, personnel costs and stock-based compensation. The period also included a $1.6 million write-off of deferred IPO costs and $2.3 million of Business Combination-related financial advisory fees.
- Operating cash use increased to $30.3 million from $15.9 million. Financing provided $146.9 million, including $111.0 million from the Business Combination, $35.0 million of convertible note proceeds and $7.9 million of RSL promissory note proceeds.
- The reverse recapitalization resulted in 54.7 million common shares outstanding at December 31, 2019, plus 10,000 Series A preferred shares and warrants exercisable for an aggregate of 5.75 million common shares.
Guidance, outlook, risks and unusual items
- Clinical programs included ASCEND-MG, ASCEND-GO 1, ASCEND-GO 2 and the planned ASCEND-WAIHA program. Management expected initial or top-line results during 2020 and early 2021, as described in the filing.
- Management expected operating expenses and capital expenditures to be funded through at least the second half of 2021 based on current plans, while the notes state that existing cash was expected to cover at least twelve months from issuance of the financial statements. These estimates depend on spending and clinical timing assumptions.
- The company expects continuing and increasing losses and has no committed external source of funds. Additional equity or debt financing may be required, potentially causing dilution or imposing restrictive terms.
- The HanAll license requires future contingent payments of up to $452.5 million under the agreement, including development, regulatory and sales milestones, reimbursement of up to $20.0 million of specified research and development costs, and tiered royalties ranging from the mid-single digits to mid-teens on net product sales. The filing states that the remaining aggregate maximum milestone payments were $442.5 million as of December 31, 2019.
- The company relies on HanAll for core intellectual property, Roivant affiliates for administrative and development services, CROs for clinical trials and third parties for manufacturing. Failure of these relationships, regulatory delays, unfavorable trial results, manufacturing problems, intellectual-property challenges or adverse safety findings could materially affect the business.
- The company had no material ongoing financial commitments other than contingent obligations under the HanAll Agreement and was not party to material legal proceedings. Its cash was held at one financial institution and exceeded federally insured limits.
- The filing references a substantial doubt about going concern expressed by the independent registered public accounting firm for the fiscal year ended March 31, 2019, although the company subsequently raised substantial financing through the Business Combination.
- RSL controlled a majority of voting power and the company qualified as a Nasdaq “controlled company.” Investors should consider related-party transactions, governance exemptions, potential dilution from equity awards and warrants, and up to 20 million potential earnout shares.
Most important facts for investors to verify
- Whether the stated cash runway through at least the second half of 2021 remains supportable after updated clinical plans, enrollment rates and spending.
- Clinical enrollment, safety, efficacy and timing of results for IMVT-1401 in MG, GO and WAIHA.
- Future financing needs, dilution from common stock, options, warrants and earnout shares, and any new debt or preferred securities.
- The status and enforceability of the HanAll license, milestone obligations, royalty terms and intellectual-property protection.
- Whether RSL-related services and governance arrangements create conflicts or operational dependence.
- Any subsequent events after February 14, 2020 that affect liquidity, clinical development, regulatory status or the going-concern assessment.